watchLAB is conducting a market research study by phone with Atrial Fibrillation patients throughout the US who have had both chemical (IV) and electrical cardioversions, preferably in the past 2 years. See below for the definitions they have supplied to help you determine if you are qualified to participate. If you qualify, you will be …
Read More
Do you know what impact atrial fibrillation has on your state? Check out the new AF Stat report, AFib in America: State Impact Reports, to identify key state-by-state statistics, resources and state health department programs related to the burden of atrial fibrillation. To learn more, see: New Analysis Illustrates the Hidden Burden of Atrial Fibrillation …
Read More
In this video, Dr. Matthew Reynolds, of the Harvard Clinical Research Institute, discussed his quality of life findings from use of catheter ablation and antiarrhythmic drugs for treatment of atrial fibrillation. He analyzed quality of life data that was collected as part of the THERMOCOOL catheter trial in which catheter ablation was found to be …
Read More
watchLAB is hosting a market research study in Los Angeles, Pittsburgh and Seattle with Atrial Fibrillation patients who have experienced both chemical (IV) and electrical cardioversion, preferably in the past 2 years. If you qualify, you will be invited to participate in a one hour interview or a small 1.5-hour group discussion to share your …
Read More
You're invited to join AF Stat™: A Call to Action for Atrial Fibrillation for the unveiling of the results of AFib in America: State Impact Reports. This first-of-its-kind analysis will feature state level statistics and resources related to the burden of atrial fibrillation (AFib) across the nation. To learn more, see: AF Stat Coalition to …
Read More
Researchers at the Comprehensive Arrhythmia Research and Management Center (CARMA) in Utah have been studying the relationship between atrial fibrillation, atrial fibrosis, and catheter ablation outcomes for many years. Now, they’ve applied their knowledge of quantifying atrial fibrosis to stroke risk assessment and found that the amount of atrial fibrosis, not type of afib, is …
Read More
New research from Denmark shows that CHADS2 underestimates stroke risk. In the study, atrial fibrillation patients who were at intermediate risk with the CHADS2 scoring system had more than twice the stroke rate of those defined by the enhanced CHA2DS2-VASc tool as being at intermediate risk. While CHADS2 deemed 32.3% of patients to have intermediate …
Read More
In this video, Dr. Kenneth Ellenbogen talks about important information presented at the American Heart Association Scientific Sessions 2010. First he talked about the ROCKET AF clinical trial of rivaroxaban, a new drug that is an alternative to warfarin (Coumadin), as well as another alternative, the recently-approved dabigatran. He provided scenarios as to how these drugs …
Read More
Hybrid ablation is an emerging treatment for patients with persistent and longstanding persistent atrial fibrillation. It is a dual approach, in which an electrophysiologist ablates from inside the heart and the cardiac surgeon ablates on the outside the heart. Dr. James Edgerton, a cardiac surgeon at The Heart Hospital Baylor Plano in Texas, who spoke …
Read More
Up to 30% of patients could have very late recurrence of atrial fibrillation after catheter ablation, according to research highlighted at the recent Boston AF Symposium. Very late recurrence, which is when atrial fibrillation resumes more than one year after ablation, may be the result of age, gender, type of afib, and existence of other …
Read More